China Fertility Services Market Overview,2030

China has greatly increased its fertility services after loosening its one-child policy, ultimately leading to the introduction of a three-child policy in 2021. This change was spurred by pressing demographic issues an aging population, decreasing birth rates, and a smaller workforce. With nearly one in six couples facing infertility, the government has made assisted reproductive technologies (ART) a key focus to aid family development and stabilize population dynamics. IVF was first brought to China in the late 1980s, and currently, the nation conducts over one million ART cycles each year, representing about 3% of the ART activity. However, despite this development, surrogacy is still completely banned under national laws established by the Ministry of Health in 2001, which prohibit both commercial and altruistic practices due to ethical, legal, and social issues. In China, ART includes IVF, ICSI, intrauterine insemination (IUI), donor gametes, and embryo freezing. These services have become more integrated into public health systems, with 27 provinces providing some insurance coverage for procedures such as IVF and embryo preservation. Clinics are offering fertility preservation options for cancer sufferers and advanced testing for issues like PCOS and luteal phase deficiency. China is now concentrating its research and development efforts on enhancing ART results through the use of artificial intelligence. Tools that utilize AI for embryo selection leveraging time-lapse imaging and deep learning techniques are being implemented to improve implantation success rates and minimize bias in embryo assessment. These systems evaluate thousands of developmental indicators to pinpoint embryos with the best chances of success, providing a non-invasive, scalable option for clinics handling a high volume of cases. As China addresses its demographic challenges, the combination of policy changes, technological advancements, and ethical regulations is forming a new, data-focused approach to fertility care.

According to the research report, ""China Fertility Service Market Overview, 2030,"" published by Bonafide Research, the China Fertility Service market is anticipated to grow at 9.19% CAGR from 2025 to 2030. This growth is driven by changing demographics, increasing infertility issues, and proactive support from the government. After the relaxation of the one-child policy and the introduction of the three-child policy, the Chinese government has implemented various measures to promote fertility. These measures include providing childcare subsidies, extending parental leave, and covering assisted reproductive technologies (ART) in public insurance across 31 provinces. The goal of these initiatives is to address falling birth rates and an aging population while making fertility services more affordable for families with middle incomes. Leading companies like Shanghai Ji Ai Genetics & IVF Institute and Angel Fertility Center are leading this growth. Shanghai Ji Ai, a prominent ART provider in the nation, offers services such as IVF, ICSI, PGT, and AI-assisted embryo selection, and has been a pioneer in third-generation IVF techniques in China. Angel Fertility, recognized for its focus on patient care and superior lab facilities, is rapidly expanding its presence in major cities and reaching out to less served areas. Although the market is expanding, there is still a significant unmet demand. Infertility impacts around 18% of couples of childbearing ages, but access to ART services is inconsistent, particularly in tier-two cities and rural regions. There are numerous opportunities to widen clinic networks, implement telemedicine for remote consultations, and create culturally relevant fertility education initiatives. The National Health Commission (NHC) is now responsible for overseeing ART compliance and human genetic resources, making the process of approvals smoother and defining ethical guidelines for both domestic and international partnerships.

China's fertility services by procedure is divided into IVF with ICSI, IUI, IVF without ICSI, Surrogacy and Others are experiencing swift changes, with in vitro fertilization (IVF) that includes intracytoplasmic sperm injection (ICSI) becoming the most rapidly developing treatment option. By 2025, IVF combined with ICSI is projected to represent a significant portion of assisted reproductive technology (ART) cycles, fueled by increasing male infertility issues, later parental decisions, and better access to cutting-edge reproductive technologies. ICSI is preferred for its accuracy in fertilization, particularly when facing challenges with sperm movement or shape, and is now readily available at both public and private fertility facilities. Intrauterine insemination (IUI) is still a popular initial treatment, especially for couples experiencing mild infertility or unknown reproductive issues. Its low cost, non-invasive approach, and growing availability in semi-urban areas make it a common step before moving on to IVF. Advances in the design of catheters and the preparation of semen have also increased the success rates of IUI, while government-supported insurance plans are starting to cover some costs for basic fertility treatments. IVF without ICSI is selectively provided, usually for couples who have good sperm quality and no previous fertilization issues. Although it is less frequently used, it remains a possible choice in low-intervention approaches and cost-sensitive environments. Surrogacy is completely prohibited in China according to rules set out by the Ministry of Health in 2001. Both paid and volunteer surrogacy arrangements are banned, and medical facilities can face repercussions for breaches. Despite the ongoing demand, legal and ethical issues have kept surrogacy out of the organized healthcare framework. Techniques like vitrification and AI-enhanced cryogenic storage systems are making long-term fertility planning possible, particularly for women who are postponing childbirth or receiving medical treatments.

In China fertility service by cause of infertility is divided into Male Infertility and Female Infertility, the issue of infertility has emerged as a significant public health challenge, with male infertility increasing and female infertility worsened by age-related declines and the long-term impacts of the one-child policy. Male infertility now accounts for almost half of all infertility instances, fueled by lower sperm quality, inactive lifestyles, environmental toxins, and heightened stress levels. While the prevalence of male infertility in China remains fairly consistent with patterns, recent research indicates that men aged 35–39 exhibit the highest rates, especially in urban areas seeking fertility assistance. In response, fertility clinics have broadened their diagnostic approaches, incorporated hormonal assessments, genetic testing, and sophisticated semen evaluations, while utilized techniques like ICSI and donor sperm programs to tackle male-related issues. In contrast, female infertility is greatly influenced by demographic factors and historical policies. The one-child policy, which was in place from 1979 to 2015, postponed reproductive planning for countless women, notably in cities where professional growth and education took precedence. Consequently, many women are now trying to conceive in their late 30s or early 40s, at a time when ovarian reserve and egg quality have notably declined. The chances of natural conception sharply decrease after age 35, and success rates for IVF also fall, leading to a greater dependence on donor eggs and embryo freezing. Women who were born during the peak of the one-child policy particularly those from the Han ethnic group face obstacles due to both age-related changes and delays in reproduction caused by policy. These patterns highlight the intricate connections between sociopolitical history, lifestyle choices, and biological factors in shaping fertility in China.

In China fertility service by end user is divided into Fertility Clinics, Hospitals, Surgical Centers and Clinical Research Institutes, the realm of assisted reproductive technology (ART) is primarily dominated by major public hospitals, which lead the delivery of services due to their large-scale operations, necessary regulatory approvals, and connections to national health insurance systems. Facilities such as Peking Union Medical College Hospital, West China Hospital, and the First Affiliated Hospital of Zhejiang University provide a range of ART services including IVF, ICSI, and embryo freezing, often facilitated by teams with diverse expertise and advanced diagnostic equipment. These hospitals act as central points for infertility treatment, especially in tier-one cities, and are increasingly integrating AI-powered tools for embryo selection to enhance success rates and lessen the number of treatment cycles required. Private fertility clinics, mainly located in urban areas like Beijing, Shanghai, and Shenzhen, work alongside public hospitals by providing quicker service, individualized treatment plans, and assistance for international patients. Establishments such as Reproductive & Genetic Hospital of CITIC-XIANGYA and Changsha AiJian IVF Center offer customized ART options, including donor gametes and fertility preservation services, often at attractive prices. Nevertheless, access to these services is inconsistent across different provinces, with rural regions experiencing limited options and higher costs for patients. Specialized surgical facilities focusing only on infertility treatments are relatively rare and are usually part of larger hospital networks. These centers conduct laparoscopic surgeries for conditions such as endometriosis, removal of fibroids, and tubal repairs, which are crucial for enhancing natural fertility or improving ART results. Despite their significance in clinical practice, these facilities are mainly found in more affluent areas and remain less developed in the western provinces.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Fertility Services Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Procedure
• IVF with ICSI
• IUI
• IVF without ICSI
• Surrogacy
• Others

By Service
• Fresh Non-Donor
• Frozen Non-Donor
• Egg and Embryo Banking
• Fresh Donor
• Frozen Donor
By Cause of Infertility
• Male Infertility
• Female Infertility

By End User
• Fertility Clinics
• Hospitals
• Surgical Centers
• Clinical Research Institutes
Show more